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Background: Data of the German population-based cohort SHIP (Study of Health in Pomerania) were analysed to
examine treatment rates, antihypertensive substances prescribed, and the proportion of hypertensive study
participants reaching target values for blood pressure as well as determinants.
Methods: The study population was defined using baseline data of the cohort (collected between 1997 and 2001).
Participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known
hypertension and participants with risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction)
and blood pressure values ≥130/80 mmHg were included. The analysis of treatment and target values was based
on the 5-year follow-up of the cohort (collected between 2002 and 2006). Logistic regression was used to identify
determinants for a normotensive blood pressure.
Results: 3278 SHIP-participants with hypertensive blood pressure values were included (mean age: 55.5 years; SD
13.6, range 21–80 years). The raw hypertension prevalence was 50.9% (N = 1761). 58.7% (N = 1074) of all
hypertensive patients reported some form of antihypertensive treatment. Thereof 65.1% (N = 728) received
combination therapy. Of the patients without risk-comorbidity, 42.1% (N = 489) reached their target blood pressure
values at the time of the 5-year follow-up of the cohort. Of the patients with any risk-comorbidity this proportion
was only 21.7% (N = 131). Significant determinants for reaching the target values were being female and having
antihypertensive combination therapy. Increasing age, having risk-comorbidities, and obesity were negatively
associated with reaching the target values.
Conclusions: Both the proportion of participants receiving therapy and the number of participants reaching their
target blood pressure values are very low. Combination therapy is associated with better blood pressure control as
compared to mono therapy. However, even in the subgroup of hypertensive patients under combination therapy
only 36% (both patients with and without comorbidity) reach target values.
Keywords: Hypertension, Antihypertensive treatment, Determinants of normotensive blood pressure, Study of
Health in Pomerania (SHIP)Background
In Germany, about half of all adults have high blood
pressure values (≥140/90 mmHg), with increasing preva-
lence in the higher age groups and higher rates in the
male population [1,2]. Compared to other countries, the
prevalence in Germany is high: in the USA hypertension
prevalence is about 28%, in Italy 38%, in the UK 42%
[3,4]. Hypertension is a risk for several secondary dis-* Correspondence: neeltje.vandenberg@uni-greifswald.de
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distribution, and reproduction in any mediumorders such as coronary heart disease, cardiac infarction,
and stroke. All these diseases are associated with high
mortality and together are the number one cause of
death in western countries.
Although patients with hypertension have various
treatment options, there are large discrepancies between
the numbers of patients with known, treated and con-
trolled hypertension [1,2].
The population representative German Health Survey
from 1998 showed, that 23.1% of the population had a
known hypertension. Population prevalence of treated
hypertension was 18.6%. In only 23.8% of all patientsentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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controlled (blood pressure values <140/90 mmHg) [5].
The proportion of both treated and controlled hyperten-
sion increases with increasing age, females are more
often treated and have controlled blood pressure values
than males. These observations have been confirmed by
different German regional cohort studies [1,2].
Most important goal of the treatment of hypertension
patients is to reach normotensive blood pressure values
to decrease the risk for secondary disorders. Reaching
normotensive blood pressure values can therefore be
considered as an indicator of the effectiveness of antihy-
pertensive therapy. According to major guidelines
targeted values are below 140/90 mmHg [6,7]. Although
targeted values below 130/80 mmHg in the current
guidelines are recommended for patients with risk-
comorbidity (diabetes, stroke, coronary heart disease,
and renal insufficiency), assessment of recent studies has
shown that the evidence for this is unclear. Nevertheless,
actual reappraisals of the guidelines recommend treat-
ment goals below 130/80 mmHg for hypertension pa-
tients with risk-comorbidity for the time being [8,9].
Pharmacotherapy of hypertension adopts a stepwise
approach. Medical treatment can start with a single anti-
hypertensive drug (monotherapy), usually an inhibitor of
the angiotensin converting enzyme (ACE). If the target
blood pressure values are not reached, the dosage should
be increased. If this doesn’t show effect, an alternative
drug should be prescribed. If the target blood pressure
values cannot be reached under monotherapy, a combin-
ation of drugs can be prescribed (combination therapy,
defined as treatment with two or more antihypertensive
drugs from different substance classes). In many cases, a
combination therapy is needed for patients with more
severe hypertension [6,7,10]. Although the evidence is
ambiguous, early treatment still is recommended [8].
In this paper, we analysed:
1. The proportion of hypertensive study participants
reaching their target blood pressure values in the
population-representative German SHIP-cohort.
Target blood pressure values are <140/90 mmHg, for
patients with risk comorbidities < 130/80 mmHg.
2. The proportions of hypertensive study participants
reaching their target blood pressure values, separate
for study participants without antihypertensive
drugs, with mono, and with combination therapy.
3. Possible determinants of reaching target blood
pressure values.
Methods
Data from the Study of Health in Pomerania (SHIP) were
included in the analysis. SHIP is an observational po-
pulation based cohort study of adult German residentsconducted in the region of Western Pomerania in north-
east Germany. The main goal of SHIP is the provision of
population-based data for the epidemiological analysis of
a broad range of diseases, risk factors, and health indica-
tors. SHIP was planned and accompanied with support
and advice from an external Data safety and Monitoring
Committee (DSMC). All participants gave written in-
formed consent. The study conforms to the principles of
the Declaration of Helsinki, as reflected by an a priori ap-
proval of the Ethics Committee of the Board of Physicians
Mecklenburg-Pomerania at the University of Greifswald.
6267 persons (age 20–79 years) with German citizen-
ship were drawn from population registries in the region
of Western Pomerania, selected persons received up to
three written invitations, followed by a telephone call or
home visit in the case of non-response. At the end, the
response was 68.7% (N = 4308) [11,12].
For this analysis we used data from the baseline
(SHIP-0, collected between October 1997 and May
2001) to define the study population of participants with
hypertension (concrete inclusion criteria: see further
below) and the 5-year-follow up (SHIP-1, collected be-
tween October 2002 and September 2006) to examine
treatment rates and determinants for controlled hyper-
tension. Lifetime prevalence was used to define risk-
comorbidity at the time of SHIP-1 [11,12].
From the 3300 persons that participated both in the
baseline study (SHIP-0) and in the 5-year-follow up of
the SHIP-study (SHIP-1), 22 participants were excluded
because of missing information about the possible pres-
ence of hypertension. The analyses were based on the
data of 3278 participants, thereof 51.9% (N = 1700) were
female.
Sociodemographic data as well as the presence of diagno-
ses and risk factors were assessed in standardized, computer-
assisted interviews and questionnaires. Blood pressure
measurements in SHIP-0 and SHIP-1 were carried out
with an automated oscillometric device (HEM-750CP,
Omron Corporation, Tokyo, Japan). The measure-
ments were conducted on the right arm after a rest
period of five minutes in a sitting position. Blood pres-
sure was measured three times at an interval of three
minutes by trained and certified personnel. The mean
value of the second and third measurement was used
in the analysis. To assess medication, the participants
were asked to bring all medication, taken during the
last seven days, with them to the examination. All
drugs were classified according to the Anatomical
Therapeutic Chemical (ATC) classification [13]. Com-
bined medical preparations were separated and classi-
fied according to each of their active substances. Drugs
were classified as antihypertensive according to the
guidelines on treatment of arterial hypertension of the
German Hypertension Society [7].
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values in need of treatment:
– study participants with blood pressure values ≥140/
90 mmHg and/or antihypertensive medication with
known hypertension;
– study participants with risk-comorbidity (diabetes,
stroke, angina pectoris, and/or myocardial
infarction) and blood pressure values ≥130/
80 mmHg. Risk-comorbidities were assessed by
asking the patients for physician-confirmed
diagnoses and the assessment of medication [11].
The participants were allocated to the different cat-
egories of the WHO/ISH-classification. This classifi-
cation has seven categories: optimal blood pressure
(syst: <120 mmHg/diast: <80 mmHg), normal (syst:
120–129 mmHg/diast:80–84 mmHg), high-normal
(syst: 130–139 mmHg/diast: 85–89 mmHg), mild hyperten-
sion (syst: 140–159 mmHg/diast: 90–99 mmHg), moderate
hypertension (syst: 160–179 mmHg/diast: 100–109 mmHg),
severe hypertension (syst: ≥180 mmHg/diast: ≥110 mmHg),
and isolated systolic hypertension (syst: ≥140 mmHg/
diast: <90 mmHg) [14].
Descriptive statistics were applied to calculate preva-
lences and treatment rates. To identify possible deter-
minants for normotensive blood pressure values, two
multivariate logistic regression models were applied.
Subjects with missing values on any of the analytical var-
iables (n = 12) were excluded. Independent variables
were sex, age, risk-comorbidity, obesity, smoking status,
household size, and antihypertensive drug therapy. The
first model includes active substances with the indication
hypertension. The second model includes the kind of
therapy (no therapy against mono or combination
therapy).
All calculations were conducted using sample-design-
weights to adjust for different selection probabilities
within the sample [11] by using the SURVEY procedures
by SAS 9.2, SAS Institute Inc., Cary, NC, USA.Results
The patients included in the different analyses are de-
scribed in the flowchart in Figure 1.Prevalences and characteristics of hypertensive study
participants
Applying the criteria described in the methods section,
in SHIP-0, 1761 of 3278 included study participants had
hypertension or blood pressure values in need of treat-
ment (raw rate: 50.9%). The age-standardized hyperten-
sion prevalence in SHIP-0 was 39.4% (females 32.0%,
males 47.3%). This prevalence can be considered asrepresentative for the region Western Pomerania in
which the SHIP cohort was recruited.
The mean age of the study participants with hypertension
in SHIP-0 was 55.5 years (SD 13.6, range 21–80 years). The
female study participants (N = 734) had a mean age of
56.7 years (SD 12.5, range 21–80 years), the male study par-
ticipants (N = 1027) 54.6 years (SD 14.2, range 21–80 years).
The hypertension prevalences increase with higher age
from 27.3% in the age group 25–34 years to 83.5% in the
oldest age group.
Table 1 shows the number of participants, allocated to
the different categories of the WHO/ISH-classification.
The highest prevalences exist in the subcategories mild
hypertension (33.6%) and isolated systolic hypertension
(27.3%). Only 15.3% of the hypertensive participants and
more females (22.4%) than males (9.7%) had blood pres-
sures lower than 140/90 mmHg (optimal, normal, or
high-normal blood pressure values).
Antihypertensive treatment
58.7% (N = 1074) of all hypertensive patients received
some antihypertensive drug treatment. Gender differences
are apparent: 67.5% of the female patients were treated,
but only 51.8% of the males (p < 0.001). The proportion of
treated hypertension patients increased with higher age.
Of all antihypertensive active substances, beta blockers
were the most frequently prescribed substance class
(63.7%, N = 671), ACE-inhibitors were taken by 52.4%
(N = 586) of the treated hypertension patients. The next
most prevalent substances were diuretics (41.1%, N = 475),
and calcium channel blockers (30.6%, N = 347). Again
there are differences between male and female patients:
males take less beta blockers and more ACE-inhibitors as
female patients (Table 2).
34.9% (N = 346) of the treated study participants re-
ceived mono therapy, 65.1% combination therapy. Gender
differences are small. The proportion of study participants
with mono therapy decreased with increasing age from
81.8% (N = 10) in the youngest age group (25–34 years) to
20.1% (N = 50) in the oldest age group (≥ 75 years).
Most combinations comprised two substances (women:
43.4%, N= 151; men: 47.1%, N = 179), the most frequent
combinations in females were ACE-inhibitors with diuretics
and ACE-inhibitors with beta-blocker (prevalences of each
combination 22.5%, N = 32). Male participants received
most frequently combinations of ACE-inhibitor with beta-
blocker (30.3%, N = 54) and ACE-inhibitor with diuretics
(15.7%, N = 28). Also combinations of three substances were
frequent (women: 37.9%, N= 132; men: 36.6%, N= 139).
Analysis of determinants for normotensive blood
pressure values
Table 3 shows the numbers and proportions of study
participants with hypertension to the time of SHIP-0
Participants SHIP-0: N=4308
Participants SHIP-1: N=3300
Participants with complete data on blood pressure 
values and risk comorbidities: N=3278
Participants in need of treatment with respect to their 
blood pressure with complete data to further chronic 
diseases: N=1754
Participants in need of treatment with respect to their 
blood pressure among SHIP-0 participants: N=1761
Participants in need of treatment  with complete data 
to all dependent variables of the logistic regression 
model: N=1749
Participants that died between SHIP-0 and 
SHIP-1 or refused to participate in SHIP-1: 
N=1008
Participants without complete data on 
blood pressure values and risk 
comorbidities: N=22
Participants not in need of treatment with 
respect to their blood pressure in SHIP-0: 
N=1517
Participants in need of treatment with 
respect to their blood pressure without 
complete data to further chronic diseases: 
N=7
Participants in need of treatment  without 
complete data to all dependent variables of 
the logistic regression model: N=5
Figure 1 Flowchart of the numbers of patients included in the analyses.
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SHIP-1, separate for study participants with and without
risk-comorbidities.
42.1% (N = 489) of the study participants without risk-
comorbidity reached their target blood pressure values.
The proportions of the female study participants show
only slight differences between study participants with
mono and with combination therapy (respectively 46.5%
and 49.0%). Regarding male patients, there are larger dif-
ferences between the patients with mono and combin-
ation therapy, 31.4% and 42.3%, respectively.
Lower target blood pressure values for patients with
risk-comorbidities are reflected in lower proportions of
normotensive patients (21.7%) in this subgroup. Regard-
ing the patients with combination therapy, only small
differences between males and females are apparent. Re-
garding the patients with mono therapy, only 5.8% of the
male patients with risk-comorbidities reach normoten-
sive blood pressure values (females: 21.8%).Table 4 shows determinants of reaching target blood
pressure values. Two regression models were calculated. In
both models, risk-comorbidity (1. model OR = 0.39; CI =
0.30-0.52, 2. model OR = 0.40; CI = 0.30-0.53), obesity (1.
model OR = 0.60; CI = 0.48-0.76, 2. model OR = 0.62; CI =
0.497-0.77), and increasing age (both models OR = 0.98;
CI = 0.97-0.99) are negative determinants for achieving the
target values. Female gender is a positive determinant (1.
model OR = 1.29; CI = 1.03-1.63, 2. model OR = 1.33; CI =
1.05-1.67). In the first model, taking at least one beta
blocker (OR = 1.28; CI = 1.01-1.64), has a positive influence
on reaching target blood pressure values. In the second
model, receiving antihypertensive combination therapy
(OR = 1.54; CI = 1.16-2.05) is a positive determinant for
achieving normotensive values.
Discussion
The analysis of the SHIP cohort provides detailed infor-
mation about prevalences of hypertension, treatment
Table 1 Classification of blood pressure values (mmHg) of hypertensive patients in the SHIP-0 cohort1 according to the
WHO-guidelines [13]
Females (N = 734) Males (N = 1027) Total (N = 1761)
N % (95% CI2) N % (95% CI2) N % (95% CI2)
optimal 23 3.0 9 0.5 32 1.6
syst: <120 mmHg/diast: <80 mmHg (1.7 – 4.3) (0.1 – 0.9) (1.0 – 2.2)
normal 53 6.8 29 2.5 82 4.4
syst: 120–129 mmHg/diast: 80–84 mmHg (4.9 – 8.7) (1.5 – 3.5) (3.4 – 5.4)
high-normal 94 12.6 78 6.7 172 9.3
syst: 130–139 mmHg/diast: 85–89 mmHg (10.1 – 15.1) (5.1 – 8.3) (7.9 – 10.7)
mild hypertension (grade 1) 215 31.3 325 35.4 540 33.6
syst: 140–159 mmHg/diast: 90–99 mmHg (27.8 – 34.7) (32.3 – 38.6) (31.3 – 36.0)
moderate hypertension (grade 2) 97 13.7 192 20.5 289 17.5
syst:160–179 mmHg/diast: 100–109 mmHg (11.2 – 16.3) (17.7 – 23.3) (15.6–19.5)
severe hypertension (grade 3) 41 5.1 80 7.1 121 6.3
syst: ≥180 mmHg/diast: ≥110 mmHg (3.5 – 6.8) (5.5 – 8.7) (5.1 – 7.4)
isolated systolic hypertension 211 27.4 314 27.2 525 27.3
syst: ≥140 mmHg/diast: <90 mmHg (24.1 – 30.8) (24.4 – 30.3) (25.1 – 29.5)
1Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with
risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg.
2CI confidence interval.
Table 2 Distribution of antihypertensive substances in hypertension patients in the SHIP-0 cohort1 to SHIP-1
Females (N = 509) Males (N = 565) Total (N = 1074)
Active agents N % (95% CI2) N % (95% CI2) N % (95% CI2)
Beta blockers 335 66.2 336 61.2 671 63.7
(61.8 – 70.5) (56.8 – 65.5) (60.6 – 66.8)
ACE-inhibitors 252 49.6 334 55.3 586 52.4
(45.0 – 54.2) (50.9 – 59.7) (49.2 – 55.6)
Diuretics 242 45.0 233 37.2 475 41.1
(40.7 – 49.4) (32.7 – 41.7) (38.0 – 44.3)
Calcium channel blocker 160 28.9 187 32.3 347 30.6
(24.9 – 32.9) (28.0 – 36.7) (27.6 – 33.6)
Angiotensin II receptor antagonists 108 20.1 98 17.3 206 18.7
(16.4 – 23.8) (13.9 – 20.6) (16.2 – 21.2)
Antiadrenergic substances3 22 4.4 34 5.4 56 4.9
(2.5 – 6.3) (3.2 – 7.7) (3.4 – 6.4)
Vasodilators4 2 0.3 1 0.2 3 0.2
(0.0 – 0.8) (0.0 – 0.5) (0.0 – 0.5)
Other types - - 1 0.2 1 0.1
(0.0 – 0.6) (0.0 – 0.3)
1Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with risk-
comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg.
2CI confidence interval.
3Both peripheral and central active antiadrenergic substances.
4Only with indication hypertension.
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Table 3 Number of hypertensive patients in the SHIP-0 cohort1 reaching target blood pressure values to SHIP-1
Female (N = 734) Male (N = 1027) Total (N = 1761)
N/Ntot % (95% CI
2) N/Ntot % (95% CI
2) N/Ntot % (95% CI
2)
Patients without risk-comorbidity3 (N = 487) (N = 680) (N = 1167)
no antihypertensive drugs 74/174 40.4 152/380 41.6 226/554 41.2
(33.0 – 47.8) (36.4 – 46.8) (37.0 – 45.5)
mono therapy 58/122 46.5 36/129 31.4 94/251 39.1
(37.3 – 55.6) (22.4 – 40.2) (32.7 – 45.5)
combination therapy 92/191 49.0 77/171 42.3 169/362 46.1
(41.4 – 56.6) (34.1 – 50.5) (40.5 – 51.6)
total 224/487 45.1 265/680 39.8 489/1167 42.1
(40.6 – 49.7) (35.8 – 43.8) (39.1 – 45.1)
Patients with risk-comorbidity4 (N = 247) (N = 347) (N = 594)
no antihypertensive drugs 17/51 33.9 13/82 13.0 30/133 21.7
(20.5 – 47.3) (5.6 – 20.4) (14.5 – 28.9)
mono therapy 8/39 21.8 3/56 5.8 11/95 12.5
(7.7 – 35.9) (0.0 – 12.5) (5.2 – 19.8)
combination therapy 37/157 21.8 53/209 26.7 90/366 24.4
(15.7 – 27.9) (19.0 – 34.5) (19.4 – 29.5)
total 62/247 24.5 69/347 19.6 131/594 21.7
(19.0 – 29.9) (14.3 – 24.8) (17.9 – 25.5)
1Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with
risk-comorbidity and blood pressure values ≥130/80 mmHg.
2CI confidence interval.
3Normotensive blood pressure: <140/90 mmHg.
4Risk-comorbidities: diabetes, stroke, angina pectoris, and/or myocardial infarction, normotensive blood pressure: <130/80 mmHg.
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tion in the region Western Pomerania.
The results of the analyses show high prevalences of
hypertension, both in the raw and age standardized rates.
Regarding medical treatment, differences between
males and females were obvious, which is similar to the
results of the German MONICA/KORA-studies [2]. Re-
garding the total group of hypertension patients, the
proportion of treated patients increases with increasing
age. Most treated patients received beta blockers, ACE-
inhibitors, and diuretics. A majority of the treated pa-
tients (67.8%) received a combination therapy, and their
proportion increases with age. Patients in the younger
age groups received more often mono therapy. Patients
with combination therapy received up to six different
antihypertensive drugs. Since the study participants were
asked to bring all their medication taken during then last
seven days to the study centre, it is likely that a high
proportion of documented drugs were actually taken by
the SHIP-participants. However, there may be a risk of
underreporting when the drugs can not be documented
in the patients’ household [15].
Although the proportion of patients treated for hyper-
tension is relatively high, only a small part of the patientsreached their target blood pressure values. Positive deter-
minants for reaching the target values were being female,
receiving combination therapy and taking beta blockers.
Negative determinants were increasing age, having risk-
comorbidity (diabetes, stroke, angina pectoris, and/or
myocardial infarction) and being obese.
The results of the analyses show that the management
of hypertension is still a challenge, especially for patients
with risk-comorbidity. A different result is shown in the
Canadian Heart Health Surveys. Here, hypertension pa-
tients with cardiovascular or cerebrovascular diseases
were more likely to reach their target values than pa-
tients without one of these diseases. The authors of the
study suggest that this unusual result depends on a
more intensive therapy to patients with a high risk or a
better compliance of these patients [16]. Erkens et al.
show in a study among hypertensive patients low per-
sistence to medication, which leads to suboptimal
treatment [17].
Nevertheless, non-adherence to antihypertensive medi-
cation may be a reason for not reaching the target blood
pressure values. The results of a study on elderly patients
of Turner et al. show that non-adherence leads to poorer
blood pressure control in this patient group [18].
Table 4 Multiple logistic regression analysis of determinants for normotensive blood pressure values
1. Model: Substances 2. Model: Therapy
Independent variables OR2 (95% CI3) OR2 (95% CI3)
Sex (ref. male)
female 1.29 (1.03–1.63) (p = 0.030) 1.33 (1.05–1.67) (p = 0.016)
Age in years (cont. variable)
0.98 (0.97–0.99) (p = 0.001) 0.98 (0.97–0.99) (p = 0.001)
Risk-comorbidity (ref. no)
yes 0.39 (0.30–0.52) (p < 0.0001) 0.40 (0.30–0.53) (p < 0.0001)
Obesity (ref. no)
yes 0.60 (0.48–0.76) (p < 0.0001) 0.62 (0.49–0.77) (p < 0.0001)
Active smoker4 (ref. no)
yes 0.97 (0.73–1.30) (p = 0.845) 0.97 (0.73–1.30) (p = 0.839)
Household size (ref. > 1 pers.)
1 person 1.19 (0.91–1.57) (p = 0.208) 1.19 (0.91–1.57) (p = 0.206)
Antihypertensive therapy(ref. no)
mono therapy - 0.93 (0.69–1.26) (p = 0.650)
combination therapy - 1.54 (1.16–2.05) (p = 0.003)
Beta blocker (ref. no)
yes 1.28 (1.01–1.64) (p = 0.044) -
ACE-inhibitors (ref. no)
yes 1.04 (0.78–1.38) (p = 0.792) -
Diuretics (ref. no)
yes 1.32 (0.95–1.84) (p = 0.097) -
Calcium channel blocker (ref. no)
yes 1.03 (0.76–1.40) (p = 0.841) -
Angiotensin II receptor antag. (ref. no)
yes 1.13 (0.76–1.67) (p = 0.546) -
Antiadrenergic substances5 (ref. no)
yes 1.16 (0.54–2.48) (p = 0.698) -
1Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with




5Both peripheral and central active antiadrenergic substances.
Model 1 considers the active substances the patients received, model 2 considers the kind of therapy (mono or combination therapy). Included are all
hypertensive patients1 to SHIP-0 with information on the independent variables to SHIP-1 (N = 1749 of in total 1761 hypertensive patients in the SHIP-0 cohort).
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related factor [19] which belongs to a variety of drug related
problems which affect treatment effectiveness [20].
Strenghts and limitations:
Strength of this analysis is the population based data
base with highly standardized blood pressure
measurement and structured assessment of
antihypertensive medication.
We only documented drugs which were brought along
by the patient to the study center. This increases data
quality but may lead to some underreporting of drugs thatwere left at home. Several other drug-related-problems as
the occurrence of drug-drug interaction may affect blood
pressure level, too.
Another limitation is the absence of data to adherence,
so the theory that treated hypertension patients with
poor blood pressure values are less adherent can not be
examined for the SHIP-participants.
Conclusions
A high prevalence of hypertension and low rates of patients
reaching target values of blood pressure values according
to pertinent guidelines were shown in the German popu-
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tions from other countries. Combination therapy is associ-
ated with better blood pressure control as compared to
mono therapy. However, even in the subgroup of hyperten-
sive patients under combination therapy only 36% (both
patients with and without comorbidity) reach target values.
Our data clearly show that patient- and provider-related
intervention strategies need to be further developed, conse-
quently implemented and prospectively evaluated.
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